510(k) K232784
K232784 is an FDA 510(k) premarket notification submitted by Alcresta Therapeutics, Inc. for the device "RELiZORB®". The FDA issued a decision of Substantially Equivalent on December 21, 2023. The device falls under product code PLQ (Enzyme Packed Cartridge), a Class II device regulated under 21 CFR 876.5985. Alcresta Therapeutics, Inc. has at least 6 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- December 21, 2023
- Date Received
- September 11, 2023
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Enzyme Packed Cartridge
- Device Class
- Class II
- Regulation Number
- 876.5985
- Review Panel
- GU
- Submission Type
Hydrolyze fats in enteral formula.